Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

Plaque psoriasis is the most common type of psoriasis ... your symptoms are flaring up or getting worse treatments recommended by your primary care doctor aren’t working you’re interested ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Before starting treatment with Otezla ... Both these drugs are used to treat plaque psoriasis and psoriatic arthritis in certain people. (Both drugs have other uses as well.) ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...